Biomea Q3 net loss narrows to $6.2M; cash of $26.8M funds runway into Q2 2027

Biomea Fusion, Inc.

Net loss attributable to common stockholders $6.2M vs $16.4M in Q3 2025; nine-month net loss $26.9M vs $66.4M.
R&D expense $8.5M, down $5.9M YoY on lower manufacturing, clinical and headcount costs; G&A $4.4M vs $4.2M.
Cash, cash equivalents and restricted cash $26.8M at Sept 30, 2026; runway projected into Q2 2027.
COVALENT-211 Phase II enrollment complete in insulin-deficient T2D; Week 26 HbA1c topline data expected Q1 2027. COVALENT-212 topline expected Q2 2027.
BMF-650 Phase I: 6.1% (6.2 kg) mean weight loss at Day 29 in Cohort 5; 1.5-3.2% in Cohorts 1-4 vs 0.1% placebo; all TEAEs mild or moderate.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.